

Index

- Abbott Laboratories, HIV vaccine clinical trial, 179
Academia. See Universities
Accelerated cost recovery system, 186
Acquired immunodeficiency syndrome
 CRADAs related to, 225
 expedited approval of therapies, 155, 156, 158
 gene therapy, 128
 Medicaid support for clinical R&D, 233
 orphan drug designation, 226
 treatments, 246
 vaccines for, 182
ADAMHA. See Alcohol, Drug Abuse and Mental Health Administration
Additional Rebate, Medicaid, 247-249
Advertising, 102
Advisory committees, FDA, 149-150
A.H. Robins, product liability litigation, 173-174, 175, 179
AIDS. See Acquired immunodeficiency syndrome
Alcohol, Drug Abuse and Mental Health Administration
 CRADA examples, 35-37, 223-225
 pharmaceutical R&D support, 213-217, 221
Alglucerase, see Ceredase™
Altshuler, marginal credit rate study, 188-189
Alzheimer's disease, 25, 120, 124-126
American Association for Accreditation of Laboratory Animal care, 64
American Casualty Excess, 173
Amgen, 230-231
Angiotensin converting enzyme, 107-108
Angiotensin converting enzyme inhibitors, 76
Angiotensin II, 107
Animal research
 necessary for INDs, 140
 cost, 13, 58, 62-65
 transgenic, 129
Animal Welfare Act, 64
Antidepressant drugs, 246
Antihistamine compounds, 110
Antihypertension drugs, 65, 76, 86, 107-108
Antimicrobial drugs, 65
Antinausea drugs, 173-174, 175-176, 179
Arthur Anderson and Company, 137
Aspirin, 108
Association of the British Pharmaceutical Industry, Great Britain, 260, 262
Australia, prescription drug benefits, 250-252
Average effective tax rate, 184
AZT, 216, 222, 246
Baber and Kang
 IRR comparison study, 96, 100-102
 worldwide tax calculation, 92
Bach-Dole Patent and Trademark Act, 35, 209
Baily, R&D cost study, 50, 136
Baily and Lawrence, tax credit study, 188, 189
Basic Rebate, Medicaid, 247
Basic research
 costs, 51, 58
 Federal support relevant to pharmaceutical R&D, 34-35, 211-213
 industry and academia collaboration, 206
 tax credits for, 189-190, 195
Bateson, William, 119
Bayliss, William, 115
Benchmark pricing scheme, Australia, 252
Bendectin, 173-174, 175-176, 179
Best, Charles, 115
Beta blockers, 76
Biogen, 226
Biomedical research
 complexity of, 131-132
 DNA as a therapeutic agent, 127-131
 drugs and drug receptors, 17, 106-113
 genetics and, 119-127
 implications for future R&D costs, 133-134
 increasing role of instruments and computers, 132
 link between basic Federal biomedical research and new drug development, 211-213
 personnel costs, 12-13, 62, 204-206
 proteins, 113-119
Biotechnology drugs
 Medicare coverage, 250
 number in development, 18, 69, 70
 orphan market exclusivity rights, 230-231
 regulatory review process, 147-149
Biotechnology industry
 cost studies, 67

- raising external capital, 9-10
- R&D spending estimates and, **41-42**
- Birth defects, 175-176
- Black, James, 110
- Blumenthal, surveys about industry and academia collaborations, academic research survey, 202, 206
- Bristol-Myers Squibb, 37,74,216-217,222
- Brown, Dr. Michael S., 74
- Brown-Séguard, Charles Edouard, 115
- “Bubble Boy Syndrome,” 128
- Burstall, M. L., 261
- Bush, George, veto of Revenue Act of 1992, 188

- Calcium channel blockers, 76,86
- Canada
 - Bill C-22, 253-254
 - Bill C-91, 255
 - prescription drug benefits, 252-255
- Cancer
 - gene therapy, 127
 - Group C drugs, 232-233
 - off-label prescriptions and, 243
- CANDAs. See Computerized new drug applications
- Capitalized R&D costs
 - cost estimate validity, 57, 59, 66-67
 - cost estimates, 16-19, 60
 - definition, 10
 - estimating R&D costs framework, 48
 - existing cost studies, 52-5,3
 - measurement difficulties, '72
- Captopril, 107-108, 118, 131
- Cardizem QD, 86
- Cash flow profile, 76, 100
- Cash outlays, R&D
 - cash costs per success, 11-15
 - clinical period, 56-57**
 - components of out-of-pocket costs, 62-65
 - framework for estimating R&D costs, 48
 - industry-level cost studies,, 60-62
 - mean cash outlay to bring new drug to market, 72
 - preclinical period, 57-58
 - present value of, 15
 - project-level cost studies, 51-54, 69
 - validity of cost estimates, 55-56, 65-66
- CBER. See Center for Biologics Evaluation and Research
- CDER. See Center for Drug Evaluation and Research
- Ceclor, 87-88
- Cefaclor, 87-88
- Cefalexin, 87
- Cell surface molecules, 112-113
- Census Bureau, 40
- Center for Biologics Evaluation and Research
 - Investigational New Drug Applications, 18
 - new drug regulatory review process, 138-139, 141-143, 148-149
 - orphan drug assistance, 227-228
 - review process guidelines, 152-153
- Center for Drug Evaluation and Research
 - cost studies, 70
 - efforts to expedite FDA new product regulations, 154-155
 - new drug classification, 142-143, 154
 - orphan drug assistance, 227-228
 - R&D spending estimates, 45
 - regulatory review process for new drugs, 138-139, 141-143, 147-149, 160
- Centers for Disease Control, 175
- Centocor, 41
- Centoxin™, 41
- Central Pharmaceutical Affairs Council, Japan, 165
- Centre for Medicines Research, United Kingdom, 40,44
- Ceredase™, 28,33,37,222-223
- CF. See Cystic fibrosis
- Cholesterol-lowering drugs, 25,74-75,216-217
- Chromosome maps. See Genetic maps
- Chugai Pharmaceuticals, 230-231
- Cimetidine, 109, 110, 131
- Clark, A.J., 106
- clinical trials
 - expedited approval process, 155-158
 - expenditures, 51, 52, 56-57
 - Federal regulatory review process for new drugs, 140, 143-146
 - Federal support for pharmaceutical R&D, 206-207, 215-217,228,232-233
 - foreign trials, 153-154
 - gene therapy, 130
 - survey of trial sizes, 14, 65
- Clowes, G. H. A., 115
- Clymer, R&D cost study, 50
- Collip, James, 115
- Comanor, William, 103
- Commercialization licenses, 36,219
- Committee for Proprietary Medicinal Products, European community, 165-166
- Compustat™ database, 100-101
 - as source of spending data, **40, 42, 43**
- Computer modeling, 63
- Computerized new drug applications, 154-155
- Computers, increasing role in biomedical research, 132
- Contraceptive devices. See Dalkon Shield
- Cooperative Research and Development agreements
 - examples, 35-37, 223-225
 - licensing inventions of Federal biomedical research labs, 36-37,219-223
 - patenting inventions of Federal biomedical research labs, 35-37,218
 - technology transfer activities, 35-37, 218
- Copayments, insurance for prescription drugs, 26-27, 240, 242, 245,255, 261
- Cost of capital, 9,93, 102
 - R&D cost estimates, 48,52-53,54,66-67
- Costs of pharmaceutical R&D.
 - components of out-of-pocket costs, 62-65
 - cost studies' approaches, 48-54
 - framework for estimating, 47-48
 - impact of regulations on, 33, 136-138
 - industry-level cost studies, 50, 60-62
 - summary, 10-19
 - tax savings from R&D, 15-16, 67-69

- trends in, 69-72
- validity of cost estimates, 14-15, 54-67
- CPAC. See Central Pharmaceutical Affairs Council
- CPMP. See Committee for Proprietary Medicinal Products
- CRADAs. See Cooperative Research and Development agreements
- Cross-licensing, 42
- CSDD. See Tufts University Center for the Study of Drug Development
- Cystic fibrosis, 121-123, 129-130

- Dalkon Shield, 173-174, 175, 179
- ddI, 37,222
- DES. See Diethylstilbestrol
- DHHS. See U.S. Department of Health and Human Services
- Diabetes, 115-117
- Diethylstilbestrol, 176
- Digitalis, 108
- DiMasi, Joseph
 - R&D cost study, 11, 14-16,50-53,55-67,68-70, 91
 - R&D expenditures estimate, 11-12,45, 166
- Diphtheria-tetanus-pertussis vaccine, 177-178
- Diuretics, 76
- DNA
 - alternative uses, 130-131
 - composition of, 114
 - gene therapy, 127-129
 - recombinant DNA, 115
- Doolittle, Russell
 - oncogene and cell growth molecule similarity, 123
- Dranove and Meltzer, regulation impact study, 138
- Drug delivery mechanisms, 6
- Drug discovery. See Biomedical research
- Drug Price Competition and Patent Term Restoration Act, 21, 22,83, 84,86,87,94
- Drug receptors, 106-113
- Drug utilization review, 244
- Drug receptors, 106-113
- DTP vaccine. See Diphtheria-tetanus-pertussis vaccine
- Duchene muscular dystrophy, 128
- DURs. See Drug utilization reviews

- EC. See European Community
- Economic Recovery Tax Act of 1981, 186-187
- Ehrlich, Paul, 106
- Eisman and Warden, regulation output study, 137
- Eisner, Albert and Sullivan, marginal tax credit rate study, 189
- ELA. See Establishment license application
- Eli Lilly and Company
 - Federal support for pharmaceutical R&D, 230
 - R&D costs, 60
 - R&D expenditures, 41
- Equipment, increasing role in biomedical research, 132
- ERTA. See Economic Recovery Tax Act of 1981
- Erythropoietin (EPO), 116
- Establishment license application, 147-149
- Ethical pharmaceuticals, 3, 26-27,42
- European Community, drug approval in, 165-167
- Exclusivity period for patents, 20-21,84,86

- Expenditures for pharmaceutical R&D.
 - allocation of funds, 44-45
 - data sources, 39-42, 166
 - domestic trends, 42
 - industry share of total biomedical R&D, 203
 - overstatement in estimates of, 40-42, 61
 - tax credits for, 68-69, 186-189
 - tax deductions for, 184-186
 - worldwide trends, 43-44

- Factor-(f) scheme, Australia, 251-252
- Faculty-founded companies, 209-210
- Failure to warn determination, 171
- FD&C Act. See Federal Food, Drug, and Cosmetic Act
- Federal Food, Drug, and Cosmetic Act, 32, 136-138
- Federal Health Facilities Research Act, 204
- Federal research laboratories, 34-37,217-225
- Federal support for pharmaceutical R&D. See Support for pharmaceutical R&D
- Federal Technology Transfer Act, 35,36,218,219, 220
- Fisher, Emil, 116
- Fluoxetine, 216, 246
- Follow-on products, 6,61
- Food, Drug, and Cosmetic Act, 206
- Food and Drug Administration
 - clinical R&D support, 215
 - efforts to expedite FDA new product regulations, 33, 151-158
 - Endocrinologic and Metabolic Advisory Committee, 74
 - NCE approvals, 54,58, 65,71
 - NME approvals, 45
 - orphan drug support, 69, 226-232
 - post-approval research and reporting requirements, 150-151
 - regulation impact on costs and output, 137
 - regulatory review process, 32-33, 52, 53, 138-151, 158-164, 167-168
- Foreign clinical trials, 65, 153-154
 - regulation trends, 164-167
 - regulatory review and foreign trials, 146
- Foreign sales
 - deduction of U.S. R&D expenses and, 185-186
- Foreign tax credits, 191-192, 193
- Foreign tax laws, 197-198, 199
- Formularies, 29, 243,246
- France, prescription drug benefits, 255-257
- French Social Security Funds, 255
- FTT. See Federal Technology Transfer Act

- Gancyclovir*, 246
- GAO. See General Accounting Office
- G.D. Searle Company, 40
- Gene therapy, 127-130
- Genentech, 60, 116,226,230
- General Accounting Office, 11,66
 - Federal product liability filings study, 174
 - tax calculation, 92
- Generic drugs
 - competition, 30
 - description, 6

- incentives to use, 30, 243
- mail-order pharmacies, 244
- market shares, 31
- in the United Kingdom, 261
- Genes. See *also* Genetics
 - composition of, 114
 - finding and studying, 119-120, 121, 123-124
 - mutations, 123-124
- Genetic maps, 120-121
- Genetics
 - DNA and, 119-120
 - gene therapy, 127-130
 - genetic factors of disease, 120
 - genetic maps, 120-121
 - history of, 119-120
 - Human Genome Project, 126-127
- Genomes, 121, 126-127
- Genzyme, Inc., 222-223
- Germ line gene therapy, 127-129
- Glaxo, worldwide sales estimates, 89
- Goldstein, Dr. Joseph S., 74
- Good Clinical Practices, 165
- Good Laboratory Practices, 165
- Government agencies. See *specific agencies by name*
- Government regulation of R&D
 - efforts to expedite FDA new product regulations, 151-158
 - Federal regulatory review process for new drugs, 138-139
 - in foreign countries, 164-167
 - impact of regulation on costs and output, 136-138
 - origins of, 135-136
 - R&D and review process trends, 158-164, 167-168
 - summary, 32-33
- Grabowski and colleagues, regulation impact study, 136-137
- Grabowski and Vernon
 - cost study, 50, 53-54
 - returns on R&D study, 78-81, 87, 89
- Group C cancer drugs, 232-233
- Guillain-Barré syndrome, 181

- H-2 receptors, 110
- Hansen, Ronald
 - R&D cost study, 11-12, 14-15, 50-53, 54, 55-67, 69, 78
 - regulation impact, 137
- Harvard University, 209
- Health Care Financing Administration, 232, 233
- Health insurance in the United States. See *also other countries by name*
 - extent of coverage, 26, 240-241
 - health maintenance organizations, 28-29, 240, 244, 245
 - hospital coverage, 238-239
 - importance in determining demand, 26-27
 - limitations on coverage, 26-27
 - Medicaid prescription drug benefits, 245-249
 - nursing home coverage, 239
 - outpatient coverage, 239-240
 - price-sensitive buyers, 28-30
 - state assistance, 249-250
- Health maintenance organizations
 - drug prescribing practices and drug price competition, 28-29, 245
 - drug utilization review programs, 244
 - prescription drug coverage, 240
- Henderson and Eisenberg, product liability study, 180
- Hill, A.V., 106
- HIV. See Human immunodeficiency virus
- HIV-antibody test kit, 220-221
- HIV hyperimmune globulin, 179
- HMG-CoA reductase inhibitors, 25, 74-75, 216-217
- HMOs. See Health maintenance organizations
- Hoffman-La Roche, 62, 63
- Human Genome Project, 126-127
- Human growth hormone, 230
- Human immunodeficiency virus
 - action of, 112
 - AZT and, 216, 222
 - CRADAs related to, 225
 - expedited approval of therapies, 156, 157
 - HIV-antibody test kit, 220-221
 - public spending on drug discovery, 213
 - vaccine for, 179
- Human recombinant soluble CD4, 226
- Humantrop[™], 230
- Hun-din, 116
- Huntington's disease, 123

- Iletin, 116
- I-MS International, Inc., 19, 89
- In-process R&D, 40-41
- In-vitro* testing, 63
- INDs. See Investigational new drug applications
- Insulin, 115-117, 132
- Internal rate of return, 23-24
 - comparative profits contractor report, 96, 100-102
 - definition, 95
 - past studies, 96
- Internal Revenue Service, 69. See *also* Tax policies
- International Conference on Harmonization, 166-167
- Intrauterine device. See Dalkon Shield
- Investigational new drug applications
 - Federal regulatory review process for new drugs, 139-143
 - Medicaid support for clinical R&D, 233
 - number of, 18-19, 45, 70-72
 - orphan drug designation, 226
 - R&D and regulatory review process trends, 158-159, 160-164
 - rewrite of regulations, 153
- Investigational Review Boards, 158
- Investment. See Returns on R&D
- IRBs. See Investigational Review Boards
- IRR. See Internal rate of return

- Japan
 - drug approval in, 164-167
 - prescription drug benefits, 257-259
- Japanese Health Insurance Bureau, 165, 257
- Japanese Pharmaceutical Affairs Bureau, 257
- Joglekar and Paterson, returns on R&D study, 78-81, 89-90

- Kang. See Baber and Kang
- Kefauver-Harris Amendments, 33, 136

- Keflex, 87
 Keystone AIDS Vaccine Liability Project, 182
 Kindt, Thomas, 224
- Liability. See Liability insurance; Product liability
 Liability insurance, 172-173
 Licensed-in drugs
 existing cost studies, 53, 54
 trends in cost of R&D, 71
 validity of R&D cost estimates, 58, 59, 70
 Licensing
 Federal patent and licensing policy, 36-37, 218
 for inventions from Federal biomedical research labs, 219-223
 Life sciences. See Biomedical research
 Lilly Pharmaceutical, 87-88, 116. See *also* Eli Lilly and Company
 Lovastatin, 74, 216-217
- Macleod, John, 115
 Mail-order pharmacies, 244-245
 Mansfield, academic research and commercial innovation survey, 201-202
 Manufacturing costs, 21-22, 90-91
 Marginal credit rate, 184, 188-189
 Marginal incentive effect, 184
 Market exclusivity, 228-231
 Marketing applications. See Foreign markets; New drug applications
 Marketing costs, 90-91, 102
 McKusick, Victor, 120
 Me-too drugs, 7, 30, 46, 73
 in France, 256
 in Japan, 257
 Medicaid
 clinical drug R&D support, 232-233
 cost-containment efforts, 247-249
 outpatient coverage, 245-246
 reimbursable amounts, 246
 reimbursable drugs, 246
 Medicaid Rebate Law, 247-249, 262-263
 Medical Science Partners, 209
 Medicare
 biotechnology drug coverage, 250
 clinical drug R&D support, 232-233
 inpatient drug coverage, 29, 239
 nursing home drug coverage, 239
 outpatient drug coverage, 239
 Meltzer. See Dranove and Meltzer
 Mendel, Gregor, 119
Mendelian Inheritance in Man, 120
 Merck & Co., 74, 216-217
 Merrell Dow Pharmaceuticals, 86
 product liability litigation, 173-174, 175-176, 179
 Mevastatin, 74
 Monsanto Corporation, 40
 Mueller and Reardon, IRR study, 103
Mutuelles, France, 255
 Myers and Shyam-Sunder, cost of capital study, 9, 66-67
 National Cancer Institute, 213, 214, 216, 225
 National Childhood Vaccine Injury Act of 1986, 181-182
 National Health Service, 259-262
 National Heart, Lung and Blood Institute, 216
 National Institute of Mental Health, 216, 225
 National Institute on Drug Abuse, 213
 National Institutes of Health
 Ceredase™ discovery, 222-223
 clinical trials involving cholesterol-lowering drugs, 216-217
 CRADAs examples, 223-225
 drug discovery and testing, 202
 gene therapy clinical trials funding, 130
 support for biomedical research, 35-37, 203, 204, 206
 targeted Federal pharmaceutical R&D programs, 210, 213-217
 technology transfer in the PHS, 218-223
 National Science Foundation, 40, 42, 204
 NCEs. See New chemical entities
 NDAs. See New drug applications
 Neutrophils, 112
 New chemical entities
 cost studies, 11-16, 49-67
 cost trends, 69-72
 description, 6-7
 allocation R&D, 45
 regulatory review process, 32-33, 150, 159, 160-164
 returns on R&D and, 19-24, 73-104
 sales, 19, 81-90
 spending estimates and, 41
 tax savings, 34, 69
 worldwide sales, 89-90
 New drug applications
 approval times, 161-163
 clinical trial survey, 65
 cost studies, 52, 53, 58-59
 cost trends, 18-19, 70, 71-72
 foreign clinical trials, 153-154
 number of, 160
 orphan drug assistance, 226, 227, 228
 regulatory review process, 32-33, 142-148, 158-159, 160-164
 rewrite of IND and NDA regulations, 33, 153
 New molecular entities
 cost trends, 18-19, 70
 funds allocation, 45
 regulatory review process, 32-33, 159, 160-164
 NIH. See National Institutes of Health
 NMEs. See New molecular entities
 NMR. See Nuclear magnetic resonance spectroscopy
 Nonsteroidal antiinflammatory drugs, 14, 65
 NSAID. See nonsteroidal antiinflammatory drugs
 NSF. See National Science Foundation
 Nuclear magnetic resonance spectroscopy, 111-113
 Nursing home coverage for prescription drugs, 239
- Off-label prescriptions, 243
 Office of Management and Budget, 231
 Office of Orphan Products Development, 226, 228
 Office of Planning and Evaluation, FDA, 160

- Office of Technology Transfer, NIX-I, 218
- Omnibus Budget Reconciliation Act of 1989, 188
- Omnibus Budget Reconciliation Act of 1990, 247
- Opportunity cost of capital, See *also* Cost of Capital, 7-8, 11, 48
- Originator products, increase in price after patent expiration, 88
- Orphan Drug Act of 1983
- effectiveness, 231, 232
 - exclusive marketing rights, 83
 - pharmaceutical R&D support, 225, 228
 - regulatory review process for new drugs, 143
 - tax savings from R&D, 16, 69
- Orphan drugs
- clinical research grants, 228
 - designation of, 226-227
 - impact of subsidies, 231-232
 - market exclusivity, 228-231
 - protocol assistance, 227-228
 - speed of approval, 71-72
 - tax credit policy, 190-191, 193, 195-196
- Outpatient coverage for prescription drugs, 239-240
- Parallel-track program, 155-156, 157
- Parker, regulation impact study, 137
- Patent and Trademark Office, 219
- Patent Policy Board, NIH, 218
- Patented Medicines Pricing Review Board, Canada, 254
- Patents
- effective patent life, 19-21, 82-87
 - exclusivity period, 84, 86
 - Federal patent and licensing policy, 36-37, 218
 - for inventions of Federal biomedical research labs, 36-37, 219
 - licensing of technology by universities, 209
 - orphan exclusivity vs. patent protection, 228-231
 - postpatent revenues, 21, 87-89
- Paterson, See Joglekar and Paterson
- Payment for prescription drugs
- in Australia, 31, 250-252
 - in Canada, 31, 252-255
 - in France, 31, 255-257
 - in Japan, 31, 257-259
 - Medicare and Medicaid support for clinical drug R&D, 232-233
 - under parallel-track program, 157
 - price discrimination, 27-28
 - sources of, 27-28
 - under Treatment IND, 156
 - in the United Kingdom, 31, 259-262
 - in the United States, 238-250
- PBPA. See Pharmaceutical Benefits Pricing Authority
- PCR. See Polymerase chain reaction
- Peltzman, regulation impact study, 136-137
- Peptic ulcer disease treatment, 109, 110
- Peptide hormones, 114-119
- Personnel costs, R&D, 12-13, 62
- Pertussis vaccine, 177-178
- Pharmaceutical Benefits Advisory Committee, Australia, 251
- Pharmaceutical Benefits Pricing Authority, Australia, 251-252
- Pharmaceutical Benefits Scheme, Australia, 251
- Pharmaceutical Manufacturers Association
- annual survey, 6
 - members' spending on research, 64, 215
 - orphan drug assistance, 226-227, 232
 - R&D costs, 53, 55, 61, 166
 - sales data annual survey, 89
 - as source of spending data, 39, 40, 41, 42, 43
 - studies of regulation's impact, 137
- Pharmaceutical Price Regulation Scheme, United Kingdom, 259-262
- Pharmaceutical R&D
- components, 7-9
 - content of, 4-5
 - costs, 17-19
 - Federal support for, 34-37, 203-206, 210-217, 234-235
 - investors and, 9-10
 - objectives, 4, 6-7
 - returns, 19-23, 73-105
 - spending, 39-46
- Phase I studies, 5, 144
- Phase II studies, 5, 144
- Phase III studies, 5, 144
- Phase IV studies, 5
- Phase-specific development times, 58-59
- Phases of clinical trials, 5, 144
- PHS. See Public Health Service
- Pioneer drugs, 7, 32, 46, 73
- PLA. See Product license application
- PMA. See Pharmaceutical Manufacturers Association
- Polymerase chain reaction, 123, 133
- Polypeptides, 114-115
- Polysaccharides, 112
- Possessions tax credits, 34, 192-193
- Pravastatin, 25, 74
- Preclinical research. See Preclinical trials
- Preclinical trials
- cost studies, 58-59, 67, 70
 - expenditures, 51, 52, 57-58
 - Federal support for pharmaceutical R&D, 213-214
- Pregnant women, anti-nausea medicine, 173-174
- Prescription drugs, 2, See *also* payment for prescription drugs
- Present value, 7-8, 15
- Price competition, 29-32
- Price discrimination, 27-28
- Pricing, Federal policies affecting, 33, 37, 221-223
- Private health insurance benefits for outpatient drugs
- drug utilization review, 244
 - extent of coverage, 240, 242
 - formularies, 243
 - generic drugs, 243
 - health maintenance organizations, 245
 - mail-order pharmacies, 244-245
 - off-label prescriptions, 243
 - reimbursable amounts, 242
 - reimbursable drugs, 242-243

- Product liability
 - data limitations, 169-170
 - failure to warn, 171
 - federal compensation for injuries, 180
 - government policy, 180-182
 - insurance for, 172-173
 - judgments against manufacturers, 174-178
 - jury awards, 172, 174-178
 - legal liability, 170-171
 - litigation trends, 173-174
 - market sham theory, 171
 - National Childhood Vaccine Injury Act of 1986, 181-182
 - strict liability, 171
 - swine flu immunization program, 181
 - tort reform, 180
 - trends, 170
 - willingness to conduct R&D and, 178-179
- Product Liability Reform Act, 180
- Product license application, 147-149, 226
- Production costs, drugs, 21-22
- Project-level cost studies
 - cost estimating approaches, 48-50
 - industry-level studies and, 60-62
 - sample of fins, 55
 - sample of NCEs, 55-56
 - study method validity, 54-55, 60
 - summary, 11-12
 - survey response accuracy, 56-60
- Proteins
 - administration of, 116-118
 - as receptors, 113-114
 - structure and function, 113
 - as therapeutic agents, 114-119
- Protropin™, 60, 230
- Public Health Service
 - pharmaceutical R&D support, 35-37, 211, 228
 - technology transfer in, 218-223
- Puerto Rico, corporate taxes, 34, 192-193

- R-zone, Japan, 258-259
- Rabies, action of, 112
- Rand Corporation
 - jury awards study, 172, 174
 - litigation trends study, 173
- Rational drug design
 - drug receptor identification and, 108-109
 - frontiers of, 111-113
- Rebates, Medicaid, 247-249
- Recombinant erythropoietin, 230-231
- Regulation and R&D. See Government regulation and R&D
- Regulatory review process. See Government regulation and R&D; U.S. regulatory review process for new drugs
- rEPO. See Recombinant erythropoietin
- Reproductive health products. See Bendectin; Dalkon Shield; Diethylstilbestrol
- Research/evaluation licenses, 219
- Research personnel, R&D costs and, 62
- Returns on R&D
 - cost of capital, 9, 93, 102
 - costs of production, 21-22
 - increasing price competition implications, 31-32
 - internal rate of return, 23-24, 95-104
 - manufacturing, marketing, and distribution costs, 90-91
 - methodology of studies, 76-77
 - net after-tax returns, 91-93
 - net cash flows, 22
 - net return on investment, 22-23
 - past studies reviewed, 76-81
 - sales curve, 19, 81-90
 - study results, 93-95
- Revenue Act of 1992, 188
- Richard, regulation impact study, 150-151
- Risks of pharmaceutical R&D, 7-9
 - high vs. low risk investment, 66-67
 - returns and risks, 46, 47-48
- RNA
 - alternative uses, 130-131
 - composition of, 114
- Royalty income, 36-37, 220-221

- Safety testing, 63, 64
- Saint George-Hyslop, Peter, 125
- Sales of New Chemical Entities
 - domestic sales, 19-20
 - effective patent life, 19-21, 82-87
 - postpatent revenues, 21, 87-89
 - worldwide sales, 19, 89-90
- Sanger, Frederick, 116, 132
- Sankyo, 74
- SAIL. See Structure-activity relationships
- Scherer, capital budgeting study, 9
- Schnee, R&D cost study, 50 “
- Self-originated drugs, description, 51
- Shining new drugs, Japan, 257, 259
- Shyam-Sunder. See *also* Myers and Shyam-Sunder
 - cost of capital update, 67
- Simvastatin, 74, 216-217
- SmithKline Beecham, 226
- SOI. See Statistics of Income Database
- SPAPs. See State Pharmaceutical Assistance Programs
- Spending. See Expenditures for pharmaceutical R&D
- Squibb, 206
- Starling, Ernest, 115
- startup firms
 - orphan drug sponsorship, **232**
 - private** industrial ventures by universities, 209-210
 - tax credits, 197
- State Pharmaceutical Assistance Programs, 249-250
- Statistics of Income Database, 193, 196
- Stevenson-Wydler Technology Innovation Act, 35, 218
- Stewart, cost of capital study, 67
- Stokes, Donald E., 213
- Strategic alliances, 41, 42
- Strict liability concept, 171
- Structure-activity relationships, 109-111
- Sturtevant, Alfred, 120
- Subpart E regulations, 155
- Support for pharmaceutical R&D
 - conclusions, 34-37, 233-235

- Federal support for biomedical research, 34-37,203-206, 232-233
- Federal support for patient-care costs, 216-217
- Federal support for R&D, facilities, 204,208-209
- industry collaboration with academia, 206-210
- industry collaboration with Federal research labs, 34-37, 217-225
- industry vs. federal support for biomedical research, 203-206
- orphan drugs, 225-232
- overview, 34-37, 201-203
- targeted Federal pharmaceutical R&D programs, 210-217
- Swine flu immunization program, 181
- TAMRA. See Technical and Miscellaneous Revenue Act of 1988
- Tax Analysts, Inc., 93
- Tax credits, 15-16, 33-34, 67
- for basic research, 34, 189-190, 195
- estimated total amount, pharmaceutical industry, 34, 193-196
- firm characteristics and, 197
- foreign tax credits, 191-192, 193
- for increases in R&D expenditures, 34,68-69, 186-189
- for orphan drugs, 34,69, '71, 190-191, 193, 195-196,231
- possessions tax credit, 34, 192-193
- relative importance, 33-34, 198-199
- Tax deductions, 15-16,67-68
- contributions to educational and scientific organizations, 186
- foreign sales and, 185-186
- qualifying R&D expenditures, 184-185
- Tax policies, 33-34, 198-199. See *also* Tax credits; Tax deductions
- composition of, 33-34, 183-184
- depreciation of capital assets used for R&D, 186
- foreign tax laws compared with U.S. laws, 197-198, 199
- net after-tax returns, 91-93
- Tax Reform Act of 1986, 186, 187, 189, 196
- Investment Tax Credit, 196
- Technical and Miscellaneous Revenue Act of 1988, 187-188
- Technology transfer
- legislative history of activities, 218
- in the Public Health Service, 35-37, 218-223
- Temin, regulation impact study, 137
- Thalidomide, 136, 179
- Thomas, Lacy Glen
- IRR study, 103
- regulation impact study, 137-138
- Toxicology testing, 140
- Training of Biomedical research personnel, 204-206
- Treatment INDs, 33, 155-15 '7, 232-233
- Tufts University Center for the Study of Drug Development
- existing studies of R&D costs, 50
- INDs for NCEs data, 71, 159, 160-162
- R&D cost estimate, 55-56, 58-59,60, 70
- United Kingdom, prescription drug benefits, 259-262
- Universities
- basic research tax credit, 189-190, 195
- Federal support of research training, 204-206
- industry and academia collaboration, 206-210
- University of Wisconsin, 209
- Upjohn Pharmaceuticals, 230-231
- U.S. Congress
- access to financial data, 11, 66
- compensation for vaccine-related injuries, 180-182
- Joint Committee on Taxation, 92, 193
- U.S. Department of Agriculture, 62-63
- U.S. Department of Commerce, 35,218
- U.S. Department of Education, 204
- U.S. Department of Health and Human Services, 36, 205, 217,220,233
- U.S. Department of the Army, 213
- U.S. regulatory review process for new drugs
- FDA role, 138-139
- guidelines, 32-33, 152-153
- investigational new drugs, 139-143
- new product applications, 143-150
- post-approval requirements, 150-151
- trends, 32-33
- U.S. Securities and Exchange Commission, as source of spending data, 40
- U.S. Supreme Court, 11,66
- U.S. Treasury Department, tax deductions for U.S. firms sales abroad, 185-186
- USDA. See U.S. Department of Agriculture
- Vaccines, product liability, 176-178, 180-182
- Venuti, Michael, 115
- Vernon. See Grabowski and Vernon
- Virts and Weston, returns on R&D study, 78-81
- Viscusi and Moore, product liability insurance and innovation study, 178
- Walden, George, 115
- Warden. See Eisman and Warden
- WARF. See Wisconsin Alumni Research Foundation
- Washington Analysis Corporation, net tax savings from possessions credit, 192
- Watson and Crick, DNA structure, 119-120
- Welwyn Laboratories, 110
- Weston. See Virts and Weston
- White House Council on Competitiveness, 157
- Wiggins, Steven
- R&D cost study, 12,50,53,54,60-61
- regulation impact study 137, 143
- Wisconsin Alumni Research Foundation, 209
- Wozny, marginal tax credit rate study, 189
- Wyatt, Richard Jed, 224
- X-ray crystallography, rational drug design and, 111-113
- X.L. Insurance Co., Ltd., 173
- Young, Frank, 231